Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard
K I
KI
Division of Medical Oncology/Haematology, Toronto-Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, Canada.
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015982:Bias; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D010052:Ovariectomy; D010053:Ovary / Q000528:radiation effects; D017697:Premenopause; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016037:Single-Blind Method; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D013629:Tamoxifen; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone